Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

Gilead Sciences Inc. (NASDAQ:GILD) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.

The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.

Also Read: Gilead Unveils ‘Remarkable Outcomes’ From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections.

The affected product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air ...